1 The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). The ocular surface 5, 75-92 (2007).
2 Pouyeh, B. et al. Impact of ocular surface symptoms on quality of life in a United States veterans affairs population. American journal of ophthalmology 153, 1061-1066.e1063, doi:10.1016/j.ajo.2011.11.030 (2012).
3 Lucca, J. A., Nunez, J. N. & Farris, R. L. A comparison of diagnostic tests for keratoconjunctivitis sicca: lactoplate, Schirmer, and tear osmolarity. The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc 16, 109-112 (1990).
4 Korb, D. R. Survey of preferred tests for diagnosis of the tear film and dry eye. Cornea 19, 483-486 (2000).
5 Stern, M. E., Schaumburg, C. S. & Pflugfelder, S. C. Dry eye as a mucosal autoimmune disease. International reviews of immunology 32, 19-41, doi:10.3109/08830185.2012.748052 (2013).
6 Lanza, N. L. et al. Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients. The ocular surface 14, 216-223, doi:10.1016/j.jtos.2015.12.007 (2016).
7 Lanza, N. L., Valenzuela, F., Perez, V. L. & Galor, A. The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye. The ocular surface 14, 189-195, doi:10.1016/j.jtos.2015.10.004 (2016).
8 Jun, J. H., Lee, Y. H., Son, M. J. & Kim, H. Importance of tear volume for positivity of tear matrix metalloproteinase-9 immunoassay. PLoS One 15, e0235408-e0235408, doi:10.1371/journal.pone.0235408 (2020).
9 Messmer, E. M., von Lindenfels, V., Garbe, A. & Kampik, A. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Ophthalmology 123, 2300-2308, doi:10.1016/j.ophtha.2016.07.028 (2016).
10 Chotikavanich, S. et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Investigative ophthalmology & visual science 50, 3203-3209, doi:10.1167/iovs.08-2476 (2009).
11 Acera, A., Rocha, G., Vecino, E., Lema, I. & Duran, J. A. Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic research 40, 315-321, doi:10.1159/000150445 (2008).
12 Schiffman, R. M., Christianson, M. D., Jacobsen, G., Hirsch, J. D. & Reis, B. L. Reliability and validity of the Ocular Surface Disease Index. Archives of ophthalmology (Chicago, Ill. : 1960) 118, 615-621 (2000).
13 McCormack, H. M., Horne, D. J. & Sheather, S. Clinical applications of visual analogue scales: a critical review. Psychological medicine 18, 1007-1019 (1988).
14 Hartig, S. M. Basic image analysis and manipulation in ImageJ. Current protocols in molecular biology Chapter 14, Unit14.15, doi:10.1002/0471142727.mb1415s102 (2013).
15 Bron, A. J., Evans, V. E. & Smith, J. A. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22, 640-650 (2003).
16 Arita, R. et al. Proposed diagnostic criteria for obstructive meibomian gland dysfunction. Ophthalmology 116, 2058-2063.e2051, doi:10.1016/j.ophtha.2009.04.037 (2009).
17 Bron, A. J., Benjamin, L. & Snibson, G. R. Meibomian gland disease. Classification and grading of lid changes. Eye (London, England) 5 ( Pt 4), 395-411, doi:10.1038/eye.1991.65 (1991).
18 Serin, D., Karsloğlu, S., Kyan, A. & Alagöz, G. A simple approach to the repeatability of the Schirmer test without anesthesia: eyes open or closed? Cornea 26, 903-906, doi:10.1097/ICO.0b013e3180950083 (2007).
19 Stevenson, W., Chauhan, S. K. & Dana, R. Dry eye disease: an immune-mediated ocular surface disorder. Archives of ophthalmology (Chicago, Ill. : 1960) 130, 90-100, doi:10.1001/archophthalmol.2011.364 (2012).
20 Aragona, P. et al. Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. Ophthalmology 122, 62-71, doi:10.1016/j.ophtha.2014.07.048 (2015).
21 Hetherington, S. V., Spitznagel, J. K. & Quie, P. G. An enzyme-linked immunoassay (ELISA) for measurement of lactoferrin. Journal of immunological methods 65, 183-190, doi:10.1016/0022-1759(83)90314-9 (1983).
22 Koczula, K. M. & Gallotta, A. Lateral flow assays. Essays in biochemistry 60, 111-120, doi:10.1042/ebc20150012 (2016).
23 Shimazaki-Den, S., Dogru, M., Higa, K. & Shimazaki, J. Symptoms, visual function, and mucin expression of eyes with tear film instability. Cornea 32, 1211-1218, doi:10.1097/ICO.0b013e318295a2a5 (2013).
24 Toda, I., Shimazaki, J. & Tsubota, K. Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis. Ophthalmology 102, 302-309, doi:10.1016/s0161-6420(95)31024-x (1995).
25 Park, J. Y., Kim, B. G., Kim, J. S. & Hwang, J. H. Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease. Translational vision science & technology 7, 31, doi:10.1167/tvst.7.5.31 (2018).
26 Pflugfelder, S. C. et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 17, 38-56, doi:10.1097/00003226-199801000-00007 (1998).
27 Bang, S. P., Son, M. J., Kim, H., Lee, Y. H. & Jun, J. H. In vitro validation of the tear matrix metalloproteinase 9 in-situ immunoassay. Scientific Reports 10, 15126, doi:10.1038/s41598-020-71977-w (2020).